Insight Molecular Diagnostics Inc. IMDX
Biotechnology: In Vitro & In Vivo Diagnostic Substances · data as of November 13, 2026
Insight Molecular Diagnostics Inc. (IMDX) is a healthcare company listed in the US with a market value of about $70M. In the twelve months to June 30, 2026 it had revenue of $2M and net income of -$49M, a net margin of -2955.6%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 27% a year, a 5-year average ROIC of -77%.
About Insight Molecular Diagnostics
Insight Molecular Diagnostics is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances. Revenue went from $1M in 2020 to $4M in 2025, growth of about 27.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 450% over three years (dilution for shareholders). It spends 392% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | $4M | $2M | $2M | $958000 | $2M | $1M | — | — | — | — |
| Net income | -$49M | -$50M | -$61M | -$28M | -$73M | -$64M | -$30M | -$22M | -$16M | -$19M | -$11M |
| Free cash flow | -$31M | -$25M | -$21M | -$24M | -$50M | -$38M | -$27M | -$21M | -$12M | -$13M | -$8M |
| EPS (diluted) | $-1.51 | $-1.65 | $-4.66 | $-3.75 | $-13.25 | $-0.72 | $-0.46 | $-440.00 | $-420.00 | $-640.00 | $-420.00 |
| Net margin | -2955.6% | -1238.5% | -3225.0% | -1848.4% | -7609.8% | -2916.2% | -2461.5% | — | — | — | — |
| ROIC | — | — | — | -122.8% | -41.5% | -68.0% | -85.2% | -51.6% | -260.7% | -237.4% | -89.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Insight Molecular Diagnostics pay a dividend?
Not currently.
Is Insight Molecular Diagnostics a good stock to buy?
We do not give buy or sell advice. Insight Molecular Diagnostics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.